• 1
    Faderl S, Kantarjian H. Novel therapies for myelodysplastic syndromes. Cancer. 2004; 101: 226241.
  • 2
    Faderl S, Kantarjian H. Myelodysplastic syndromes. In: DeVitaV, HellmanS, RosenbergS, editors. Cancer: principles & practice of oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005: 21442154.
  • 3
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189199.
  • 4
    Harris NJ, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1977. J Clin Oncol. 1999; 17: 38353849.
  • 5
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 20792088.
  • 6
    Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002; 200: 19972004.
  • 7
    Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579585.
  • 8
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415428.
  • 9
    Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia. 2000; 14: 586593.
  • 10
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 24292440.
  • 11
    Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 24412452.
  • 12
    Anonymous. NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. Oncology (Huntington). 1998; 12: 5380.
  • 13
    Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89: 6771.
  • 14
    Jadersten M, Montgomery SM, Astermark J, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor and erythropoietin: response and impact on survival in a long-term follow-up of 129 patients. Blood. 2003; 02: 184a.
  • 15
    Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120: 10371046.
  • 16
    Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Int Med. 2002; 137: 156163.
  • 17
    Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997; 79: 15481551.
  • 18
    Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 102: 30253027.
  • 19
    Saunthararajah Y, Nakamura R, Nam J-M, et al. HLA-DR15 (DR2) is overexpressed in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002; 100: 15701574.
  • 20
    Steensma DP, Dispenzieri A, Breanndan S, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003; 101: 21562158.
  • 21
    Thomas DA, Giles FJ, Cortes J, et al. Antiangiogenic therapy in leukemia. Acta Haematol. 2001; 106: 190207.
  • 22
    Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001; 98: 958965.
  • 23
    Moreno-Aspitia A, Geyer S, Li C-Y, et al. N998B: multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). Blood. 2002; 100: 96a.
  • 24
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549557.
  • 25
    Kurzrock R, Kantarjian HM, Cortes J, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003; 102: 45274534.
  • 26
    Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004; 22: 12871292.
  • 27
    Feldman EJ, Cortes J, Holyoake TL, et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood. 2003; 102: 421a.
  • 28
    Tomasson MH, Williams IR, Hasserjian R, et al. TEL/PDGFbR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999; 93: 17071714.
  • 29
    Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347: 481487.
  • 30
    Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood. 2002; 100: 10881091.
  • 31
    Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003; 97: 27602766.
  • 32
    Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18: 956962.
  • 33
    Saba H, Rosenfeld C, Issa JP, et al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood. 2004; 104: 23a.
  • 34
    O'Brien S, Issa JP, Ravandi-Kashani F, et al. Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract]. J Clin Oncol. 2005; 23: 571s.
  • 35
    Feldman EJ, Seiter KP, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996; 10: 4042.
  • 36
    Fenaux P, Morel P, Rose C, Lai JL, Jouet J, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol. 1991; 77: 497501.
  • 37
    de Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) after MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer (EORTC-LCG). Leukemia. 1995; 9: 18051811.
  • 38
    Wattel E, DeBottom S, Lai JL, et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol. 1997; 98: 983991.
  • 39
    Bernasconi C, Alessandrino EP, Bernasconi P, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukemia evolving from MDS. Br J Haematol. 1998; 102: 678683.
  • 40
    Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997; 99: 939944.
  • 41
    Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996; 88: 24732479.
  • 42
    Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999; 17: 28192830.
  • 43
    Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997; 90: 29692977.
  • 44
    Estey E, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin and/or all-trans retinoic acid granulocyte-colony stimulating factor in poor prognosis newly-diagnosed non-APL AML and MDS. Blood. 1999; 93: 24782484.
  • 45
    Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Haematol. 2000; 72: 139150.
  • 46
    Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome — covariate-adjusted comparison of five regimens. Cancer. 2001; 92: 19992015.
  • 47
    Guilhot F, Bouabdallah R, Desablens B, et al. Topotecan, cytosine arabinoside and G-CSF (TAG) versus idarubicin, cytosine arabinoside and G-CSF (IDAG) in patients with myelodysplastic syndrome (MDS) or MDS in transformation: a randomized phase III study. Blood. 2002; 100: 98a.
  • 48
    Kell W, Burnett A, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003; 102: 42774283.
  • 49
    Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to the standard AML treatment improves long-term outcome in high tumor burden and older than 40 years acute myeloid leukemia patients. Five-year follow-up of the polish adult leukemia group (PALG 1999 DAC vs. DA study) [abstract]. Blood. 2004; 104: 497a.
  • 50
    Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004; 18: 989997.
  • 51
    Russo D, Malagola M, Martinelli G, et al. Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years [abstract]. Blood. 2004; 104: 250a.
  • 52
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1965; 53: 457481.
  • 53
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 54
    Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 23792386.